Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000548806 | SCV000626226 | likely benign | Fanconi anemia | 2024-09-02 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000674060 | SCV000799333 | uncertain significance | Fanconi anemia complementation group A | 2018-04-13 | criteria provided, single submitter | clinical testing | |
Genomic Medicine Center of Excellence, |
RCV000674060 | SCV004801156 | pathogenic | Fanconi anemia complementation group A | 2024-03-14 | criteria provided, single submitter | research | |
Kasturba Medical College, |
RCV000674060 | SCV005046845 | likely pathogenic | Fanconi anemia complementation group A | criteria provided, single submitter | clinical testing | ||
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV005001073 | SCV005625531 | uncertain significance | not provided | 2024-04-12 | criteria provided, single submitter | clinical testing | The FANCA c.964C>T (p.His322Tyr) variant has been reported in the published literature in an individual affected with Fanconi anemia (FA) in a homozygous state (PMID: 34585473 (2021)). The frequency of this variant in the general population, 0.00046 (14/30616 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is benign. Based on the available information, we are unable to determine the clinical significance of this variant. |
Fulgent Genetics, |
RCV000674060 | SCV005646678 | uncertain significance | Fanconi anemia complementation group A | 2024-01-10 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000674060 | SCV001457965 | uncertain significance | Fanconi anemia complementation group A | 2020-09-16 | no assertion criteria provided | clinical testing |